LearnGlossaryMarketStocksSuperinvestorsSign in

COYA

Coya Therapeutics, Inc.

Healthcare · $118M market cap

Verdict

We can't put a fair value on COYA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-14.4% a year✗
Sales growth15.1% a year✓
Free cash flow growth—?
Return on invested capital-36.1%✗

Follow COYA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds COYA. Who we track

David Einhorn

Greenlight Capital · as of Q4 2023

$9.4M

1,274,026 shares

About Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works